Fast Five Quiz: Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos, MD


January 11, 2022

A triplet regimen is standard therapy for relapsed/refractory multiple myeloma. Patients who cannot tolerate a triplet regimen can be started on a doublet regimen.

Patients are generally treated with the triplet regimen as continuous therapy. If a patient is eligible for ASCT and it was deferred at relapse, three to six induction cycles are usually done before stem cell harvest.

ASCT improves median overall survival in multiple myeloma by approximately 12 months, but randomized trials demonstrated a similar overall survival between both early ASCT (immediately after four cycles of induction therapy) and delayed ASCT (at the time of relapse as salvage therapy).

Learn more about treatment of multiple myeloma.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.